Weekly Digest - 15-21 Apr 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 15-21 Apr 2023
April 16, 2023: Tafasitamab-cxix (IV) / DLBCL / Morphosys / Incyte: 5 Year data from L-MIND study demonstrated prolonged, durable responses
MorphoSys and Incyte reported 5-year follow-up data from ACCR 2023 for Phase 2 L-MIND trial investigating Tafasitamab plus Lenalidomide combination as 2L+ treatment for patients with R/R DLBCL
- Data demonstrated Tafasitamab-cxix + Lenalidomide followed by Tafasitamab monotherapy provided prolonged, durable responses in R/R DLBCL
- Overall response rate (ORR) was 57.5% with 1 complete response in 41.2% of patients and 1 partial response in 16.2% of patients
- The median overall survival was 33.5 months and median progression-free survival was 11.6 months
- No new safety signals were identified
- In July 2020, Tafasitamab + Lenalidomide received accelerated approval based on ORR by US FDA for the treatment of adult patients with R/R DLBCL
